Validation of two predictive models for survival in pulmonary arterial hypertension
- 2 April 2015
- journal article
- research article
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 46 (1) , 152-164
Abstract
The French Pulmonary Hypertension Network (FPHN) registry and the Registry to Evaluate Early And Long-term Pulmonary Arterial Hypertension Disease Management (REVEAL) have developed predictive models for survival in pulmonary arterial hypertension (PAH). In this collaboration, we assess the external validity (or generalisability) of the FPHN ItinérAIR-HTAP predictive equation and the REVEAL risk score calculator.Validation cohorts approximated the eligibility criteria defined for each model. The REVEAL cohort comprised 292 treatment-naïve, adult patients diagnosed <1 year prior to enrolment with idiopathic, familial or anorexigen-induced PAH. The FPHN cohort comprised 1737 patients with group 1 PAH.Application of FPHN parameters to REVEAL and REVEAL risk scores to FPHN demonstrated estimated hazard ratios that were consistent between studies and had high probabilities of concordance (hazard ratios of 0.72, 95% CI 0.64–0.80, and 0.73, 95% CI 0.70–0.77, respectively).The REVEAL risk score calculator and FPHN ItinérAIR-HTAP predictive equation showed good discrimination and calibration for prediction of survival in the FPHN and REVEAL cohorts, respectively, suggesting prognostic generalisability in geographically different PAH populations. Once prospectively validated, these may become valuable tools in clinical practice.Keywords
This publication has 38 references indexed in Scilit:
- Validation of the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) pulmonary hypertension prediction model in a unique population and utility in the prediction of long-term survivalThe Journal of Heart and Lung Transplantation, 2012
- REVEAL: a contemporary US pulmonary arterial hypertension registryEuropean Respiratory Review, 2012
- Prognostic factors in severe pulmonary hypertension patients who need parenteral prostanoid therapy: The impact of late referralThe Journal of Heart and Lung Transplantation, 2012
- Development of prognostic tools in pulmonary arterial hypertension: Lessons from modern day registriesThrombosis and Haemostasis, 2012
- Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management EraCirculation, 2010
- Predicting Survival in Pulmonary Arterial HypertensionCirculation, 2010
- Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertensionEuropean Respiratory Journal, 2010
- Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equationEuropean Respiratory Journal, 2009
- A meta-analysis of randomized controlled trials in pulmonary arterial hypertensionEuropean Heart Journal, 2008
- An epidemiological study of pulmonary arterial hypertensionEuropean Respiratory Journal, 2007